Sinovac Biotech Ltd.’s (SVA) H1N1 Vaccine Passes Experts Evaluation Organized by SFDA

(PRNewswire-Asia) — Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac’s H1N1 vaccine has passed the experts evaluation organized by State Food and Drug Administration (SFDA). The vaccine is expected to obtain the production license within this week.

On August 30 and 31, 2009, State Food and Drug Administration (SFDA) organized and held an experts evaluation conference focused on A/H1N1 vaccines to evaluate Sinovac’s H1N1 vaccine, which has recently completed a clinical trial. Top-line results from the trial demonstrated Sinovac’s H1N1 vaccine to have a good safety profile and immunogenicity factors that reach the EU criterion after a single shot. No severe adverse events were reported after inoculation. Based on the results of the evaluation, the experts unanimously agreed that Sinovac’s H1N1 vaccine is applicable to all people from 3 to 60 years old and the vaccination schedule is single shot. The result of the experts evaluation conference will be submitted to SFDA on September 1st, which will be the primary opinion for SFDA to issue the production license.

Sinovac submitted the H1N1 split influenza vaccine without adjuvant for registration approval, which is applicable to all people from 3 to 60 years old. The dosage is 15ug/0.5ml/dose. Only one shot is needed for inoculation.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac commented, “We are very excited to see that our H1N1 vaccine has passed the experts evaluation conference organized by SFDA. The evaluation result will be the important opinion for SFDA to issue the production license. We expect to obtain the production license within one week. With this approval, we can continue to fulfill our mission to provide top-quality vaccines to prevent and control the spreading of H1N1 virus not only in China, but worldwide.”

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac’s vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac’s pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

AuthenTec (AUTH) Expands Software Team and Presence in China

Servotronics, Inc. (SVT)

Servotronics, Inc. has established a reputation for its design, development, and manufacture of high quality components, systems and sub-systems for use wherever precise control, reliability and cost containment are required. The company’s products include servocontrol valves, torque motors, actuators, check valves, pressure regulators, metallic seals and many other products which are used in a wide range of applications and industries.

Servotronics is committed to delivering customer satisfaction by meeting and exceeding their product requirements for value, quality, reliability, and on-time deliveries. The company views all challenges as achievement based opportunities for continuous improvement. Viewing itself as a team player, Servotronics’ synergistically combines its employees’ expertise, efforts and support to create the cutting edge of technology and value.

Currently the company trades at a P/E of 6.8 and Market Cap of $18.15 Million. With annual sales of $31.66 Million, the company trades at a Price/Sales Ratio of only 0.45. Over the past five years, annual net income has grown at an average of 60.85% versus the industry average of 12.11%.

In 2010, the company generated net income of $2,128,000 (or $1.01 per share diluted) on revenues of $31,659,000. This compares to net income of $1,903,000 (or $0.98 per share diluted) on revenues of $33,008,000 during 2009, an approximate 11.8% increase in net income.

As of last report, Servotronics had $28.5 Million in assets, $3.2 Million in current liabilities and $3.1 Million in long-term debt. Shareholder equity totals $21.3 Million providing a solid Debt/Equity Ratio of 0.01. The company also boasts a respectable 46.8% Return on Equity, 40.8% Return on Assets and 46.2% Return on Capital.

Key statistics (5/3/11):

Market cap: $18.15 Million
P/E Ratio: 6.8 versus industry average of 13.4
P/S Ratio: 0.45 versus industry average of 0.54
Price/Cash Flow Ratio: 6.20 versus industry average of 10.70

Debt/Equity Ratio: 0.01 versus industry average of 0.43
Current Ratio: 8.9 versus industry average of 0.4
Quick Ratio: 8.9 versus industry average of 0.1
Book Value/Share: $10.75 versus current market price of $9.16

Return on Equity: 46.8% versus industry average of 19.7%
Return on Assets: 40.8% versus industry average of 7.3%
Return on Capital: 46.2% versus industry average of 5.3%
Inventory Turnover: 5.8 versus industry average of 1.9

Tiens Biotech Group, Inc. (TBV)

Tiens Biotech Group, Inc. conducts most of its business through two of its subsidiaries: Tianjin Tianshi Biological Development Co., Ltd., and Tiens Yihai Co., Ltd. Founded in 1998, Tianjin Tianshi focuses on researching, developing, manufacturing and marketing supplements and personal care products. Tiens Yihai on the other hand focuses on the research and development, production and marketing of nutrition supplements products, home care and personal care products.

Tiens’ herbal products, vitamin and mineral supplements and personal care products are sold in China as well as approximately 90 other countries. The company has significantly increased its revenue and earnings over the years by capitalizing on worldwide consumer demand for nutritional and wellness products. Tiens has positioned itself for further growth through product line enhancements and additional channels of distribution.

As a result of its ongoing R&D efforts, Tiens has developed, manufactured and marketed more than 20 major products and launches 5-to-7 new products each year. Attracting world-class talent to develop its high-quality products, Tiens has built modern research laboratories with superior scientific equipment and provides competitive compensation packages for the research staff. In addition to developing its own products, the company also plans to utilize product acquisitions to expand its product portfolio.

Currently, insiders hold 95.09% of the shares outstanding, which gives them great incentive to protect and build shareholder value. In addition to growing revenues and earnings at such a rapid and consistent rate, the management team has also proven their competence by providing Return on Equity (ROE) of 14.7%, Return on Assets of 11.4%, and Return on Capital of 14.2%. These returns are dramatically higher than the average percentages and speak volumes of the company’s effectiveness.

Key statistics (5/6/10):

Market cap: $155 Million
P/E Ratio: 6.6 versus industry average of 14.2
P/S Ratio: 2.56 versus industry average of 3.65
Price/Cash Flow Ratio: 5.8 versus industry average of 11.2

Debt/Equity Ratio: 0.00 versus industry average of 0.48
Current Ratio: 2.0 versus industry average of 2.7
Quick Ratio: 1.9 versus industry average of 1.9
Book Value/Share: $2.47 versus current market price of $2.17

Return on Equity: 14.7% versus industry average of 12.4%
Return on Assets: 11.4% versus industry average of 4.7%
Return on Capital: 14.2% versus industry average of 6.6%
5-Year average ROE: 20.8% versus industry average of 8.7%

Recent News

Five Star Quality Care, Inc. (FVE)

Five Star Quality Care, Inc. is a national healthcare and senior living services provider focused on building a solid financial base by carefully managing assets, resulting in a better bottom-line and enhanced resident care. With more than 21,000 employees in 230 locations nationwide, the company operates through three major divisions: Five Star Senior Living, Five Star Rehabilitation Services, and Five Star Pharmacy Services.

The Five Star Senior Living division includes more than 200 Independent Living and Assisted Living facilities, Skilled Health Care facilities, and Continuing Care Retirement Communities. Through its Rehabilitation Services division, Five Star operates rehabilitation hospitals and outpatient health rehabilitation clinics. Through its Pharmacy Services division, Five Star operates institutional pharmacies across the country.

There is much opportunity for the company to grow as the aging U.S. population increases demand for independent living properties, assisted living communities, skilled nursing facilities, pharmacies and rehabilitation services. In addition to capitalizing on this industry growth, the company aims to improve profitability of its existing operations by increasing revenues and improving margins. Five Star is also utilizing a proven acquisition strategy for growth and continues to seek additional areas of expansion.

With more than a billion in annual revenues, the company trades at a market cap of $181.8 million, providing a price to sales ratio of only 0.15! Few investors foresee a decline in stock price coming any time soon with less than 4% of the float reportedly shorted. Two analysts currently believe the company is a “Buy”, while one other believes it’s a “Hold”. Currently 46.50% of the shares outstanding are held by institutions while 11.92% are held by insiders.

Most experienced investors would assume at this point that Five Star must have a poor balance sheet and/or revenues are declining, but the company actually has a solid balance sheet with $25.7 million in cash, and revenues have grown at an average of 14.81% the past five years.

Key statistics (12/10/10):

Market cap: $254.70 Million
P/E Ratio: 13.4 versus industry average of 9.3
P/S Ratio: 0.20 versus industry average of 0.93
Price/Cash Flow Ratio: 7.10 versus industry average of 74.60

Debt/Equity Ratio: 0.31 versus industry average of 1.91
Current Ratio: N/A versus industry average of 1.1
Quick Ratio: 1.0 versus industry average of 0.2
Book Value/Share: $4.46 versus current market price of $7.13

Return on Equity: 12.7% versus industry average of -3.4%
Return on Assets: 4.7% versus industry average of 0.5%
Return on Capital: 7.8% versus industry average of 0.8%
Receivable Turnover: 19.9 versus industry average of 27.4